Pricing Log in Create free account
Saturday 31 October 2026 Export GILD’s income statement to Excel — free account

Gilead Sciences, Inc.

GILD Healthcare Drug Manufacturers General

Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS fell 638.2%, free cash flow grew 376.8% and total debt rose 5.21%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; dividend growth for ten consecutive years.

170.84 5.23 +3.16%
Market cap
$205.4B
P/E
0.0×
Fwd P/E
−45.5×
Dividend yield
1.90%
F-score
8/9
Altman Z
4.03
Beneish M
−2.45
Dividend safety
77/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Filings

Gilead Sciences, Inc. (GILD) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 11 added · 7 removed · 35 modified
P2I1A: 1 removed · 29 modified
8-K Oct 29, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 33 added · 8 removed · 31 modified
P2I1A: 2 added · 1 removed · 28 modified
8-K Aug 4, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 14, 2026 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K May 7, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 30, 2026 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits
8-K Apr 28, 2026 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 4 added · 9 removed · 34 modified
1A: 11 added · 7 removed · 43 modified
7: 39 added · 41 removed · 48 modified
8-K Feb 22, 2026 1.01 Entry into a material definitive agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Feb 10, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Nov 15, 2025 5.02 Departure or appointment of directors or officers Officer departure
10-Q Sep 30, 2025
8-K Oct 30, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 6, 2025 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K Aug 7, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K Apr 24, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024
8-K Feb 11, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Nov 6, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Aug 8, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 25, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 6, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Nov 7, 2023 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.